Drugs / METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
last change Sep 2023 re-read 2 minutes ago

METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF

Developed for
urinary bladder cancer

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01812369 Comparator Feb 2013 → Sep 2023 urinary bladder cancer University Hospital, Rouen Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF ClinicalTrials.gov intervention name — accepted as the source's own label NCT01812369